Response to “Doubt About the Feasibility of Preemptive Genotyping”

E-ISSN： 1532-6535|93|3|234-234

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.93, Iss.3, 2013-03, pp. : 234-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Doubt About the Feasibility of Preemptive Genotyping

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 3, 2013-03 ,pp. : 233-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 235-242

John Wiley & Sons Inc

Access to resources Recommend Favorite

Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management

CLINICAL AND TRANSLATIONAL SCIENCE (ELECTRONIC), Vol. 8, Iss. 4, 2015-08 ,pp. : 272-280

John Wiley & Sons Inc

Access to resources Recommend Favorite

Doulas’ Perspectives about Providing Support to Incarcerated Women: A Feasibility Study

PUBLIC HEALTH NURSING, Vol. 32, Iss. 4, 2015-07 ,pp. : 316-326

John Wiley & Sons Inc

Access to resources Recommend Favorite

Limits to doubt

By Fredriksen Ståle

Theoretical Medicine, Vol. 26, Iss. 5, 2005-10 ,pp. : 379-395

Springer Publishing Company

Access to resources Recommend Favorite